You can buy or sell ARCT and other stocks, options, ETFs, and crypto commission-free!
Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. Read More The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Simply Wall StMar 8
Investors Who Bought Arcturus Therapeutics (NASDAQ:ARCT) Shares A Year Ago Are Now Down 18%
It’s easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both better or worse than that. Investors in Arcturus Therapeutics Ltd. (NASDAQ:ARCT) have tasted that bitter downside in the last year, as the share price dropped 18%. That falls noticeably short of the market return of around 0.9%. Arcturus Therapeutics hasn’t been listed for long, so although we’re wary of recent listings that perform poorly, it may still prove itself with time. And the shar...
Stock Price, News, & Analysis for Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 p...
Expected Mar 18, Pre-Market